ClinicalTrials.gg
CompletedNCT04220996RECONNECTUpdated Apr 20, 2021

Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD)

A Phase 4 interventional study of Vortioxetine in MDD and Anxiety Disorders, sponsored by H. Lundbeck A/S. Completed at 21 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-04-20.

Sponsored by H. Lundbeck A/S · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 56 studies in Anxiety Disorders with a site in Poland — 12 open to participants now, 12 under way, none of them phase 3. Anxiety Disorders · Poland.

Enrollment
21st of 39
100 · median 104
Started
2019
with 3 others
Phase 4
3 of 56
none open now
Registered
18th of 56
by date

Among the 56 studies in Anxiety Disorders with a site in Poland, this one is the 21st largest by enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2019, is one of 3 in phase 4, and was the 18th registered.

Anxiety Disorders

7,220 studies on the registry are indexed under Anxiety Disorders; 1,682 are open to participants now.

Browse Anxiety Disorders studies →

Open to participants now

12 of the 56 studies in Anxiety Disorders with a site in Poland are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 946 Anxiety Disorders studies recruiting now, 419 (44%) set no upper age limit and 459 (49%) stop at 75 or younger; 234 take children under 18; 318 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Anxiety Disorders with a site in Poland, or all of them as a file.
02

Study summary

This study evaluates the effectiveness of vortioxetine on depressive symptoms in patients with depression coexisting with generalized anxiety disorder.

Read the detailed description

100 patients, recruited from psychiatrist outpatient clinics are planned for enrolment. Approximately 50 of these patients will receive vortioxetine as a first treatment for the current Major Depressive Episode (MDE) (first treatment patients) and 50 patients will be switched to vortioxetine due to inadequate response to the current antidepressant medication treatment (switch patients).

03

Conditions studied

  • MDD
  • Anxiety Disorders

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient has a primary diagnosis of MDE, diagnosed according to ® confirmed using the Mini International Neuropsychiatric Interview (MINI).
  • The patient has had the current MDE for \<12 months
  • The patient has current comorbid Generalized Anxiety Disorder (GAD) according to DSM-5®. The diagnosis was made prior to the current MDE
  • The patient has a Montgomery and Åsberg Depression Rating Scale (MADRS) total score ≥ 22 at the Baseline Visit
  • The patient has a Hamilton Anxiety Rating Scale (HAM-A) score ≥ 20 at the Baseline Visit

Exclusion criteria

Exclusion Criteria:

  • The patient has any current psychiatric disorder or Axis I disorder (® criteria), established as the primary diagnosis, other than MDD, as assessed using the Mini International Neuropsychiatric Interview (MINI) or another diagnostic interview.
  • The patient has a history of previous major depressive episodes considered as treatment resistant, defined as inadequate response (incomplete or no therapeutic response) to two prior courses of at least 6 weeks of conventional antidepressant drugs in adequate dosages or, the patient has treatment-resistant depression in the investigator's opinion.

Other in- or exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Vortioxetine

    10-20 mg vortioxetine tablets

    Drug: Vortioxetine

Interventions

  • Vortioxetine 10 and 20 mg/day, tablets, orally Patients will receive 10 mg vortioxetine once daily for the first week. At Visit 2, the dose will be increased to 20 mg/day. The dose may subsequently be adjusted to 10 or 20 mg/day at scheduled or unscheduled visits depending on patient's response as per investigator judgment.

06

What researchers measure

Primary outcomes

  1. Change in Montgomery and Åsberg Depression Rating Scale (MADRS) total score

    The Montgomery and Åsberg Depression Rating Scale (MADRS) is a 10-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom). The total score of the 10 items ranges from 0 to 60, with higher values indicating worse outcome.

    Time frame: from baseline to Week 8

Secondary outcomes

  1. Change in Hamilton Anxiety Rating Scale (HAM-A) total score

    The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 indicate very severe anxiety.

    Time frame: from baseline to Week 8

  2. Change in Hospital Anxiety and Depression Scale (HADS) total score

    The HADS is a patient-rated scale designed to screen for anxiety and depressive states in medical patients. It consists of two sub-scales: the D-scale measures depression and the A-scale measures anxiety. Each sub-scale contains 7 items, and each item is rated from 0 (absent) to 3 (maximum severity). The score of each sub-scale ranges from 0 to 21.

    Time frame: from baseline to Week 8

  3. Change in Functioning Assessment Short Test (FAST) total score

    The FAST is a valid and reliable instrument, easy to apply which requires a short period of time to administer. Evaluates functioning taking into account the last 15 days. It was developed for the clinical evaluation of the main difficulties presented by psychiatric patients, and has been validated in several languages for patients with bipolar disorder. The FAST scale consists of 24 items which allow the assessment of six specific areas of functioning: autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal relationships and leisure time. Each item is rated on a 4-point scale from 0 (no difficulty) to 3 (severe difficulty). The items are summed to yield a total score ranging from 0 to 72 with higher scores reflecting more serious difficulties.

    Time frame: from baseline to Week 8

  4. Change in Clinical Global Impression - Severity of Illness (CGI-S) score

    The Clinical Global Impression severity of illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients).

    Time frame: from baseline to Week 8

  5. Clinical Global Impression Scale- Global Improvement (CGI-I) score

    The Clinical Global Impression - global improvement CGI-I provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).

    Time frame: At Week 8

  6. Change in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) total score

    The original Q-LES-Q is a patient self-rated scale designed to measure the degree of enjoyment and satisfaction experienced by patients in various areas of daily life. It consists of 93 items to measure: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. Each item is rated on a 5-point scale ranging from 1 (very poor) to 5 (very good).

    Time frame: from baseline to Week 8

07

Study locations

21 sites
  • Marienthali Kliinik (EE0001)
    Tallinn, Estonia
  • Tartu University Hospital (EE0002)
    Tartu, Estonia
  • Cabinet du Docteur Patrick Bourgoin (FR0002)
    Angoulême, France
  • Cabinet Psyche (FR0004)
    Douai, France
  • Cabinet du Docteur Karim Boutayeb (FR0001)
    Viersat, France
  • Centre Medical Ambroise Pare (FR0003)
    Élancourt, France
  • Azienda Ospedaliera di Perugia - Policlinico Monteluce (IT0003)
    Perugia, Italy
  • Fondazione Santa Lucia IRCCS (IT0002)
    Rome, Italy
  • Inje University Ilsan Paik Hospital (KR0002)
    Goyang-si, Korea, Republic of
  • Chonnam National University Hospital (KR0003)
    Gwangju, Korea, Republic of
  • Samsung Medical Center (KR0001)
    Seoul, Korea, Republic of
  • MlynowaMed Specjalistyczny Psychiatryczny Gabinet Lekarski Joanna Lazarczyk (PL0009)
    Białystok, 15-404, Poland
  • NZOZ Dom Sue Ryder - Pallmed Sp. z o.o. (PL0003)
    Bydgoszcz, Poland
  • CareClinic (PL0005)
    Katowice, Poland
  • Centrum Zdrowia Psychicznego Biomed - Jan Latala (PL0001)
    Kielce, Poland
  • Niepubliczny Zaklad Opieki Psychiatrycznej Mentis (PL0004)
    Leszno, Poland
  • Centrum Medyczne Luxmed Sp.Z O.O. (PL0006)
    Lublin, Poland
  • Clinical Research Center Spolka z ograniczona odpowiedzialnoscia Medic-R Sp.k. (PL0007)
    Poznan, Poland
  • Nzoz Syntonia (PL0010)
    Pruszcz Gdański, 83-000, Poland
  • Hospital Clinic de Barcelona (ES0003)
    Barcelona, Spain
  • Instituto Internacional de Neurociencias Aplicadas (ES0001)
    Barcelona, Spain
08

References and documents

Publications

  • Christensen MC, Schmidt S, Grande I. Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study. J Psychopharmacol. 2022 May;36(5):566-577. doi: 10.1177/02698811221090627. Epub 2022 May 2. PubMed 35499104 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Mar 2021, 14 months.

Of 59 phase 4 interventional studies under Anxiety Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2020
First posted
Jan 7, 2020
StartActual
Dec 27, 2019
Primary completionActual
Mar 9, 2021
CompletionActual
Mar 9, 2021
Last update
Apr 20, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04220996
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Jan 7, 2020
Start date
Dec 27, 2019
Primary completion
Mar 9, 2021
Completion
Mar 9, 2021
Last update
Apr 20, 2021

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@Lundbeck.com

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion